Stockreport

Amgen Refocuses Pipeline As Rocatinlimab Exit Reshapes Dermatology Outlook [Yahoo! Finance]

KIRIN HLDGS CO LTD S/ADR  (KNBWY) 
US:NASDAQ Investor Relations: kirinholdings.co.jp/english/ir
PDF Amgen (NasdaqGS:AMGN) has ended its collaboration with Kyowa Kirin on the atopic dermatitis drug rocatinlimab. The decision is tied to portfolio prioritization and re [Read more]